Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes
worldwide. The number affected is increasing rapidly with alarming trends in children and …

Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

Background Diabetes is one of the leading causes of death and disability worldwide, and
affects people regardless of country, age group, or sex. Using the most recent evidentiary …

Background Accurate data on type 1 diabetes prevalence, incidence, associated mortality
and life expectancy are crucial to inform public health policy, but these data are scarce. We …

Aims To provide global, regional, and country-level estimates of diabetes prevalence and
health expenditures for 2021 and projections for 2045. Methods A total of 219 data sources …

Executive summary Liver diseases have become a major health threat across Europe, and
the face of European hepatology is changing due to the cure of viral hepatitis C and the …

Up to 50% of the people who have died from COVID-19 had metabolic and vascular
disorders. Notably, there are many direct links between COVID-19 and the metabolic and …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline
for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of …

Aim To report the point prevalence, deaths and disability-adjusted-life-years (DALYs) due to
type 2 diabetes and its attributable risk factors in 204 countries and territories during the …